Unregistered Sales of Equity Securities and Use of Proceeds
−Removed: (a) Recent Sales of Unregistered Securities
−Removed: (b) Use of Proceeds from Initial Public Offering
+Added: Recent Sales of Unregistered Securities
+Added: Use of Proceeds from Initial Public Offering
Not applicable.
−Removed: (c) Issuer Purchases of Equity Securities
−Removed: Total Number of
−Removed: Shares (or Units)
−Removed: Average Price Paid
−Removed: per Share (or Unit)
−Removed: Total Number of
−Removed: Shares (or Units)
−Removed: Part of Publicly
−Removed: Announced Plans or
−Removed: Maximum Number
−Removed: or Approximate Dollar
−Removed: Value of Shares
−Removed: (or Units) that
−Removed: May Yet be Purchased
−Removed: Under the Plans or
−Removed: April 1, 2020 - April 30, 2020
−Removed: May 1, 2020 - May 31, 2020
−Removed: June 1, 2020 - June 30, 2020
−Removed: Represents shares of restricted common stock of Magenta Therapeutics, Inc.
−Removed: repurchased in connection with the termination of a certain employee’s employment with Magenta Therapeutics, Inc.
−Removed: Under the terms of the applicable restricted stock award agreement, such shares were repurchased by Magenta Therapeutics, Inc.
−Removed: at the amount originally paid by such employee for such shares.
+Added: Issuer Purchases of Equity Securities
Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant’s Current Report on Form 8-K (File No.
6 unchanged sentences
333-225178) filed with the Securities and Exchange Commission on May 24, 2018).
+Added: First Amendment to Employment Agreement, executed as of October 14, 2020, by and between the Registrant and John C.
+Added: Davis, Jr., M.D.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10 unchanged sentences
Furnished herewith.
+Added: Represents management compensation plan, contract or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MAGENTA THERAPEUTICS, INC.
−Removed: August 6, 2020
−Removed: /s/ Jason Ryan
−Removed: Chief Operating and Financial Officer
+Added: November 5, 2020
+Added: /s/ Cindy Driscoll
+Added: Cindy Driscoll
+Added: Treasurer and Vice President, Finance
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.